J. Joseph and K. Rodvold, The role of carbapenems in the treatment of severe nosocomial respiratory tract infections, Expert Opinion on Pharmacotherapy, vol.43, issue.4, pp.561-75, 2008.
DOI : 10.1086/425368

J. Balfour, H. Bryson, and R. Brogden, Imipenem/Cilastatin, Drugs, vol.51, issue.1, pp.99-136, 1996.
DOI : 10.2165/00003495-199651010-00008

M. Wolff, M. Joly-guillou, and O. Pajot, Les carbap??n??mes, R??animation, vol.18, issue.2, pp.199-208, 2009.
DOI : 10.1016/S1624-0693(09)75318-6

L. Lee, M. Kinzig-schippers, A. Nafziger, L. Ma, F. Sörgel et al., Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation, Diagnostic Microbiology and Infectious Disease, vol.68, issue.3, pp.251-259, 2010.
DOI : 10.1016/j.diagmicrobio.2010.06.012

A. Rodloff, E. Goldstein, and A. Torres, Two decades of imipenem therapy, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.916-945, 2006.
DOI : 10.1093/jac/dkl354

J. Mouton, D. Touzw, A. Horrevorts, and A. Vinks, Comparative Pharmacokinetics of the Carbapenems, Clinical Pharmacokinetics, vol.10, issue.2, pp.185-201, 2000.
DOI : 10.2165/00003088-200039030-00002

W. Craig, State???of???the???Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men, Clinical Infectious Diseases, vol.26, issue.1, pp.1-10, 1998.
DOI : 10.1086/516284

S. Zelenitsky, R. Ariano, and G. Zhanel, Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data, Journal of Antimicrobial Chemotherapy, vol.66, issue.2, pp.343-352, 2011.
DOI : 10.1093/jac/dkq348

J. Roberts and . J. Lipman, Pharmacokinetic issues for antibiotics in the critically ill patient, Critical Care Medicine, vol.37, issue.3, pp.840-51, 2009.
DOI : 10.1097/CCM.0b013e3181961bff

F. Pea, P. Viale, and M. Furlanut, Antimicrobial Therapy in Critically Ill Patients, Clinical Pharmacokinetics, vol.28, issue.12, pp.1009-1043, 2005.
DOI : 10.2165/00003088-200544100-00002

R. Mehrotra, D. Gaudio, R. Palazzo, and M. , Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness, Intensive Care Medicine, vol.28, issue.12, pp.2145-56, 2004.
DOI : 10.1007/s00134-004-2428-9

B. Boucher, G. Wood, and J. Swanson, Pharmacokinetic Changes in Critical Illness, Critical Care Clinics, vol.22, issue.2, pp.255-71, 2006.
DOI : 10.1016/j.ccc.2006.02.011

H. Belzberg, J. Zhu, E. Cornwell, J. Murray, J. Sava et al., Imipenem Levels Are Not Predictable in the Critically Ill Patient, The Journal of Trauma: Injury, Infection, and Critical Care, vol.56, issue.1, pp.111-118, 2004.
DOI : 10.1097/01.TA.0000056164.26493.28

D. Mckindley, B. Boucher, M. Hess, M. Croce, and T. Fabian, Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia, Pharmacotherapy, vol.16, issue.5, pp.924-955, 1996.

I. Tegeder, A. Schmidtko, L. Bräutigam, A. Kirschbaum, G. Geisslinger et al., Tissue distribution of imipenem in critically ill patients, Clinical Pharmacology & Therapeutics, vol.71, issue.5, pp.325-358, 2002.
DOI : 10.1067/mcp.2002.122526

A. Novelli, C. Adembri, P. Livi, S. Fallani, T. Mazzei et al., Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis, Clinical Pharmacokinetics, vol.28, issue.3, pp.539-588, 2005.
DOI : 10.2165/00003088-200544050-00007

S. Sakka, A. Glauner, J. Bulitta, M. Kinzig-schippers, W. Pfister et al., Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial, Antimicrobial Agents and Chemotherapy, vol.51, issue.9, pp.3304-3314, 2007.
DOI : 10.1128/AAC.01318-06

S. Jaruratanasirikul and T. Sudsai, Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion, Journal of Antimicrobial Chemotherapy, vol.63, issue.3, pp.560-563, 2009.
DOI : 10.1093/jac/dkn543

J. Conil, B. Georges, S. Ruiz, T. Rival, T. Seguin et al., Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations, British Journal of Clinical Pharmacology, vol.45, issue.C, pp.61-71, 2011.
DOI : 10.1111/j.1365-2125.2010.03793.x

J. Crandon, R. Ariano, S. Zelenitsky, A. Nicasio, J. Kuti et al., Optimization of meropenem dosage in the critically ill population based on renal function, Intensive Care Medicine, vol.51, issue.4, pp.632-640, 2011.
DOI : 10.1007/s00134-010-2105-0

L. Garcia-capdevila, C. López-calull, C. Arroyo, M. Moral, M. Mangues et al., Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients, Journal of Chromatography B: Biomedical Sciences and Applications, vol.692, issue.1, pp.127-159, 1997.
DOI : 10.1016/S0378-4347(96)00498-7

M. Lavielle and F. Mentré, Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX Software, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, pp.229-278, 2007.
DOI : 10.1007/s10928-006-9043-z

URL : https://hal.archives-ouvertes.fr/inserm-00156907

A. Samson, M. Lavielle, and F. Mentré, Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-74, 2006.
DOI : 10.1016/j.csda.2006.05.007

URL : https://hal.archives-ouvertes.fr/inserm-00182360

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1058, 2005.
DOI : 10.1016/j.csda.2004.07.002

S. Beal, Ways to fit a PK model with some data below the quantification limit, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.5, pp.481-504, 2001.
DOI : 10.1023/A:1012299115260

L. Gall, J. Lemeshow, S. Saulnier, and F. , A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study, JAMA: The Journal of the American Medical Association, vol.270, issue.24, pp.2957-63, 1993.
DOI : 10.1001/jama.1993.03510240069035

J. Vincent, R. Moreno, J. Takala, S. Willatts, D. Mendonça et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure, Intensive Care Medicine, vol.21, issue.7, pp.707-717, 1996.
DOI : 10.1007/BF01709751

C. Gómez, J. Cordingly, and M. Palazzo, Altered pharmacokinetics of ceftazidime in critically ill patients, Antimicrob Agents Chemother, vol.43, issue.7, pp.1798-802, 1999.

J. Pickering, C. Frampton, R. Walker, G. Shaw, and Z. Endre, Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients, Critical Care, vol.16, issue.3, p.107, 2012.
DOI : 10.2215/CJN.08531109

M. Herrera-gutiérrez, G. Seller-pérez, E. Banderas-bravo, J. Muñoz-bono, M. Lebrón-gallardo et al., Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a??single-center study, Intensive Care Medicine, vol.75, issue.1, pp.1900-1906, 2007.
DOI : 10.1007/s00134-007-0745-5

S. Herget-rosenthal, T. Quellmann, C. Linden, M. Hollenbeck, V. Jankowski et al., How does late nephrological co-management impact chronic kidney disease? - An observational study, International Journal of Clinical Practice, vol.50, issue.4 Suppl. 3, pp.1784-92, 2010.
DOI : 10.1111/j.1742-1241.2010.02535.x

URL : https://hal.archives-ouvertes.fr/hal-00592307

D. Mould and R. Upton, Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development???Part 2: Introduction to Pharmacokinetic Modeling Methods, CPT: Pharmacometrics & Systems Pharmacology, vol.14, issue.4, p.38, 2013.
DOI : 10.1177/0091270010376965

H. Thai, F. Mentré, N. Holford, C. Veyrat-follet, and E. Comets, Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics, Journal of Pharmacokinetics and Pharmacodynamics, vol.27, issue.3, pp.15-33, 2014.
DOI : 10.1007/s10928-013-9343-z

URL : https://hal.archives-ouvertes.fr/inserm-00939284

M. Bergstrand, A. Hooker, J. Wallin, and M. Karlsson, Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models, The AAPS Journal, vol.13, issue.2, pp.143-51, 2011.
DOI : 10.1208/s12248-011-9255-z

J. Ribbing, J. Nyberg, O. Caster, and E. Jonsson, The lasso???a novel method for predictive covariate model building in nonlinear mixed effects models, Journal of Pharmacokinetics and Pharmacodynamics, vol.32, issue.2, 2007.
DOI : 10.1007/s10928-007-9057-1

K. Yoshizawa, K. Ikawa, K. Ikeda, H. Kumon, H. Ohge et al., Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data, International Journal of Antimicrobial Agents, vol.40, issue.5, pp.427-460, 2012.
DOI : 10.1016/j.ijantimicag.2012.06.011

P. De-paepe, F. Belpaire, and W. Buylaert, Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock, Clinical Pharmacokinetics, vol.21, issue.14, pp.1135-51, 2002.
DOI : 10.2165/00003088-200241140-00002

Y. Tanigawara, R. Sato, K. Morita, M. Kaku, N. Aikawa et al., Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus, Antimicrobial Agents and Chemotherapy, vol.50, issue.11, pp.3754-62, 2006.
DOI : 10.1128/AAC.00420-05